Towards Healthcare
Anti-Viral Nasal Spray Market Size & Worldwide Demand

Anti-Viral Nasal Spray Market Size and Developments

The anti-viral nasal spray market is projected to grow significantly from 2024 to 2034 due to rising viral infections, increasing immunity concerns and demand for needle-free, self-administered options. North America and Asia-Pacific lead the market, with children being the primary users.

Anti-Viral Nasal Spray Market Size, Shares and Segmental Growth

The global anti-viral nasal spray market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2024 to 2034. This surge is attributed to evolving consumer preferences and technological advancements reshaping the industry.

The demand for anti-viral nasal sprays is growing because of growing infectious diseases. A drop in immunity has been noticed due to various factors like lifestyle, pollution, and changing environment, which leads to weak immunity and increases the chances of getting infections. 

Market Overview

The anti-viral nasal spray market deals with the manufacturing and distribution of anti-viral nasal spray. Nasal sprays are used to deliver medications directly to the nasal cavities as an alternative to pills or injections. Nasal sprays are used to administer medical drugs, antibiotics, antibodies, and vaccines. The demand for anti-viral nasal sprays is growing due to the growing number of patients with infections. Apart from this, nasal sprays also provide several advantages over the conventional route, such as needle-free delivery and self-administration, the fact that they do not require refrigeration, and the lower logistical burden. Nasal sprays hold the potential to reduce infectious viral load transformation.

  • In July 2024, an investigational nasal vaccination that could offer wider protection against new SARS-CoV-2 strains is the subject of a Phase 1 study to evaluate safety. Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Diseases at the National Institutes of Health (NIH) are funding the first-in-human study of the experimental vaccine. The vaccine was created and tested in pre-clinical trials.

Nasal Vaccines Can be the Next Thing in Anti-Viral Nasal Spray

Bacterial, viruses, fungi, and other pathogens usually infect the host via cells of respiratory mucosa. Due to this, nasal sprays hold great potential in providing strong mucosal and systemic immunity. Compared to traditional methods, nasal sprays are easily accessible, provide self-help vaccination, are comfortable, and enhance individual compliance. Many vaccines have been developed for viral infections; however, not many have been approved by the FDA yet. However, in the future, with research and development and clinical trials, more and more vaccines are going to be approved and applied via nasal cavities using nasal sprays.

Side Effects of Nasal Sprays

Although nasal sprays have several advantages, they also have side effects, which restrain the growth of the anti-viral nasal spray market. People who use nasal sprays may show several side effects, such as nosebleeds, headaches, weakness, anxiety, nausea, stringing, and nose irritation, which is why people refrain from using nasal sprays.

Regional Insights

North America dominated the anti-viral nasal spray market in 2023.

There is a growing need for novel and inventive nasal sprays due to the rising incidence of nasal ailments. The region's strong healthcare system and cutting-edge research facilities are the main drivers of its success. Therefore, the growth of the market in the area may be attributed to rising healthcare costs and investments in research and development for the creation of nasal sprays. Furthermore, the nasal spray market in the area has grown due to the presence of major players in the industry, a rise in product releases, and rising consumer awareness and demand.

Clinical Diagnosis for Influenza Infection In the U.S., 2023-2024

Unlock Infinite Advantages: Subscribe to Annual Membership

The graph shows the number of specimens tested for influenza virus and the number of specimens that were positive. The positive number increases the chances of adopting nasal sprays for treatment.

In the U.S., there is an increasing need for nasal sprays as a result of increased viral infection rates. The U.S. is mainly concentrating on branded nasal producers that are interested in creating distinctive goods in order to comply with new regulatory procedures. Because nasal drug delivery is more convenient for patients to use and has better efficacious properties, it is expected that the anti-viral nasal spray market will develop at a faster rate over the projected period.

For instance,

  • In September 2024, the only influenza vaccination that may be applied to oneself in the US is called FluMist. FluMist is a needleless nasal spray that may be self-administered by adults up to 49 years old or given to people 2–17 years old by a parent or caregiver.

Growing Cases of Viral Infection Drives Asia Pacific’s Market

Asia Pacific is expected to grow at the fastest rate during the forecast period. Potential unrealized in emerging nations with rising healthcare knowledge and disposable income. Online prescriptions and consultations are available to make nasal medicines easy to deliver. In addition, the anti-viral nasal spray market in India was increasing at the quickest rate in the Asia-Pacific region, while China's market continued to have the greatest share.

A rise in respiratory illnesses among youngsters in northern China has been seen by the World Health Organization (WHO) since mid-October 2023, based on data from Chinese surveillance systems. Chinese authorities have emphasized since mid-October the need to improve the ability of the health system to manage patients in addition to improving disease surveillance in medical institutions and community settings.

Six Nipah virus infections with laboratory confirmation were reported by the Indian Ministry of Health and Family Welfare between September 12 and 15, 2023. In response, the government established containment zones in nine villages inside the Kozhikode district. These zones imposed social separation, mobility limitations, and mask wearers' obligatory attendance in public areas. In order to address infectious diseases that are of significance to the entire world, the Indian government also launched the Infectious Disease Biology Program. To accomplish the objectives of sustainable development, the program funds research and development initiatives. Under this initiative, research on the molecular mechanisms of pathogenesis, host-pathogen interactions in viral infections, and fundamental disease biology is encouraged and supported.

Segmental Insights

By effective protection duration, the 6 hours and more segment dominated the anti-viral nasal spray market in 2023 and is expected to remain dominant through the forecast period. The growth of the segment is attributed to the need for long-lasting therapeutics. For better results and fast recovery, nasal sprays that have long-lasting effects are preferred over those that do not last longer. With growing cases of infections, people prefer nasal sprays that will boost their immunity to tackle the virus for longer periods.

By application, the children segment held the largest market share in 2023. Children are more susceptible to infectious diseases due to their weaker immune systems. Apart from this, nasal sprays are preferred for children because they are painless and safety-wise better for children. Apart from this, it also reduces the number of hospital visits, which makes children more susceptible to infections.

Recent Developments

  • In August 2024, two novel nasal sprays for respiratory viruses, such as the flu and COVID-19, have been created by University of Houston researchers. Those with impaired immune systems will be most affected by the therapy, which aims to activate their immune system and try to rebuild it.
  • In February 2022, Nitric Oxide Nasal Spray (FabiSpray), developed in collaboration with SaNOtize, is now available in India for the treatment of adult COVID-19 patients. Glenmark is a globally recognized pharmaceutical firm with its headquarters in Mumbai.

Top Companies in the Anti-viral Nasal Spray Market

  • Blue Sail Medical
  • Cipla
  • Pneumagen
  • Starpharma
  • Glenmark Pharmaceuticals
  • Guangzhou Apollobio
  • Melbourne Company
  • Novasci
  • Birmingham Biotech
  • Dual
  • Virx
  • EM Pharma
  • Profispray
  • Biosure
  • Salvacion
  • pHOXBIO

Segments Covered in the Report

By Effective Protection Duration

  • 6 Hours or Less
  • 6 Hours or More

By Application

  • Children
  • Adults
  • Elderly

By Region

  • North America 
    • U.S.
    • Canada
  • Asia Pacific 
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe 
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America 
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA) 
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Insight Code: 5255
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

Meet the Team

Kesiya Chacko is a healthcare market research expert with 4+ years of experience, specializing in analyzing industry trends, assessing market opportunities, and providing actionable insights for businesses in healthcare sectors.

Learn more about Kesiya Chacko

Aditi Shivarkar, with 14+ years of healthcare market research experience, ensures the accuracy, clarity, and relevance of reports. Her expertise helps businesses make informed decisions and stay competitive in healthcare sectors.

Learn more about Aditi Shivarkar
FAQ's

Nasal sprays act faster and provide a better immunity boost than other methods. Nasal sprays are painless, unlike injections, and can be administered without any involvement of healthcare professionals.

Nasal spray should be used once or twice a day.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO.